Targeting PDGF Signaling in Carcinoma-Associated Fibroblasts Controls Cervical Cancer in Mouse Model

The authors discuss a new study of a paracrine regulatory circuit centered on PDGF receptor signaling in cancer-associated fibroblasts and pericytes of a mouse model of cervical carcinoma.

[1]  D. Hanahan,et al.  Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting , 2008, PLoS medicine.

[2]  T. Mccauley,et al.  Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. , 2007, Cancer research.

[3]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[4]  R. Jain,et al.  Platelet-derived growth factor receptor-β in Gorham's disease , 2006, Nature Clinical Practice Oncology.

[5]  T. Ngoma.  World Health Organization cancer priorities in developing countries. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  K. Do,et al.  Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. , 2006, Journal of the National Cancer Institute.

[7]  Holger Gerhardt,et al.  Pericytes limit tumor cell metastasis. , 2006, The Journal of clinical investigation.

[8]  R. Jain,et al.  Platelet-derived growth factor receptor-beta in Gorham's disease. , 2006, Nature clinical practice. Oncology.

[9]  Z. Werb,et al.  PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival , 2005, Nature Cell Biology.

[10]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[11]  C. Marosi,et al.  Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-α, -β, c-kit, c-abl, and Arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate Therapy , 2005, Journal of Neuro-Oncology.

[12]  S. Waggoner.  Cervical cancer , 2003, The Lancet.

[13]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[14]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[15]  R. Pazdur,et al.  Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.